Clinical trial
A Phase 3 Randomized Study to Evaluate Survival of Patients Treated With Talaporfin Sodium (LS11) and Interstitial Light Emitting Diodes (LED) as Compared to the Standard of Care Therapies in the Treatment of Unresectable Hepatocellular Carcinoma (HCC)
NCT00355355 is registered in ClinicalTrials.gov with Light Sciences Oncology as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 3 Randomized Study to Evaluate Survival of Patients Treated With Talaporfin Sodium (LS11) and Interstitial Light Emitting Diodes (LED) as Compared to the Standard of Care Therapies in the Treatment of Unresectable Hepatocellular Carcinoma (HCC)
- Lead sponsor
- Light Sciences Oncology
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- July 31, 2006
- Completion date
- September 30, 2012
- Enrollment
- 208 (actual)
- Sites
- 34
Conditions
As the registry lists them; a condition with its own page is linked.